Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06686576

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2025-12-18

363

Participants Needed

1

Research Sites

311 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer

CONDITIONS

Official Title

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed written informed consent
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Untreated pathologically confirmed colon adenocarcinoma
  • Radiographic assessment showing resectable stage IIB-III (cT4 or cN+ only) based on AJCC Stage VIII
  • Tumor demonstrating microsatellite instability-high or defective mismatch repair (MSI-H/dMMR)
  • Adequate organ function as described in the protocol
Not Eligible

You will not qualify if you...

  • Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy
  • Presence of distant metastatic disease
  • Active autoimmune disease requiring systemic treatment in the past 2 years
  • Known history of or evidence of interstitial lung disease
  • Active infection requiring systemic therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Affiliated Cancer Hospital of Sun Yat-sen University

Guangzhou, China

Actively Recruiting

Loading map...

Research Team

R

Ruihua Xu, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | DecenTrialz